Pharmaceutical formulation comprising lanosterol, derivative thereof, and cyclodextrin

The combination of lanosterol derivatives with cyclodextrin derivatives in specific formulations addresses solubility and stability issues, enhancing bioavailability and anti-inflammatory effects, thereby improving therapeutic efficacy.

WO2024228549A1PCT designated stage expired Publication Date: 2024-11-07CARBOEXPERT INC +1
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
PCT/KR2024/005931
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-02
Filing Date
2024-05-02
Publication Date
2024-11-07

AI Technical Summary

Technical Problem

Cyclodextrins have limitations in solubilizing and stabilizing therapeutic agents, leading to unpredictable bioavailability and reduced efficacy of drug-cyclodextrin complexes, and many compounds are unsuitable for pharmaceutical use due to solubility and stability issues.

Method used

A pharmaceutical formulation combining lanosterol or its derivatives with cyclodextrin derivatives, specifically gamma-cyclodextrin, at various molar ratios to enhance solubility, stability, and bioavailability, and to improve anti-inflammatory effects, using methods like ultrasonic treatment and high-pressure homogenization to form inclusion complexes.

Benefits of technology

The formulation significantly increases the water solubility and bioavailability of lanosterol derivatives, enhances their anti-inflammatory effects, and improves stability, as demonstrated by improved absorption and reduced cytokine expression in inflammatory models.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure KR2024005931_07112024_PF_FP_ABST
    Figure KR2024005931_07112024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to a pharmaceutical formulation comprising lanosterol, a derivative thereof, and cyclodextrin. The pharmaceutical formulation, according to one aspect, exhibits enhanced water solubility and absorption in the body and thus has the effect of increased bioavailability.
Need to check novelty before this filing date? Find Prior Art

Description

Pharmaceutical formulations comprising lanosterol and its derivatives and cyclodextrin

[0001] It relates to a pharmaceutical formulation comprising lanosterol and its derivatives and cyclodextrin.

[0002] Cyclodextrins have pharmaceutical applications and are used to solubilize or stabilize many compounds, but their therapeutic applications are limited, as many compounds are either incapable of cyclodextrin complexation or have disadvantages that render them unsuitable for pharmaceutical use [see J. Szejtli, Pharmaceutical Technology, 1991, 24-38; and U.S. Patent No. 5,362,860]. In particular, the bioavailability of drug: cyclodextrin mixtures is often unpredictable, and in fact, drug: cyclodextrin complexation can often reduce drug bioavailability [see T. Loftsson, Pharmaceutical Technology, 1999, 12, 40-50; and Uekama, K, et al., CRC Critical Reviews in therapeutic Drug Carrier Systems, 1987, 3(1), 1-40].

[0003] Meanwhile, research has been conducted to isolate useful compounds from Chaga mushrooms, and various compounds such as inotodiol, trametenolic acid, lanosterol, and inonotsulide have been isolated (Ma L. et al., 2013). Lanosterol and its derivatives have been shown to possess physiological activities such as anticancer, anti-inflammatory, and anti-allergic properties.

[0004] The present inventors have completed the invention of a pharmaceutical preparation for enhancing the physiological activity of lanosterol and its derivatives.

[0005] One aspect is to provide a pharmaceutical formulation comprising a compound represented by the following chemical formula 1 or a pharmaceutically acceptable salt thereof; and a cyclodextrin derivative represented by the following chemical formula 2.

[0006] [Chemical Formula 1]

[0007]

[0008] [Chemical Formula 2]

[0009]

[0010] In the above chemical formula 1, R1 to R 10 is independently H, substituted or unsubstituted alkyl having C1 to C4, substituted or unsubstituted alkenyl having C2 to C4, substituted or unsubstituted alkynyl having C2 to C4, substituted or unsubstituted alkoxy having C1 to C4, halogen, hydroxy, aldehyde, carboxy, amino, nitro, or cyano,

[0011] In the above chemical formula 1 Is , , , or am.

[0012] In the above chemical formula 2, n is 4, 5 or 6, and R11, R12, R13, R14, R15, R16, R17, R18 and R19 are independently -OH, substituted or unsubstituted alkoxy having 1 to 4 carbon atoms, or substituted or unsubstituted alkylthio having 1 to 4 carbon atoms.

[0013] Another aspect is to provide a method for preparing the above formulation.

[0014] One aspect provides a pharmaceutical formulation comprising a compound represented by the following chemical formula 1 or a pharmaceutically acceptable salt thereof; and a cyclodextrin derivative represented by the following chemical formula 2.

[0015] [Chemical Formula 1]

[0016]

[0017] [Chemical Formula 2]

[0018]

[0019] In the above chemical formula 1, R1 to R 10 is independently H, substituted or unsubstituted alkyl having C1 to C4, substituted or unsubstituted alkenyl having C2 to C4, substituted or unsubstituted alkynyl having C2 to C4, substituted or unsubstituted alkoxy having C1 to C4, halogen, hydroxy, aldehyde, carboxy, amino, nitro, or cyano,

[0020] In the above chemical formula 1 Is , , , or am.

[0021] In the above chemical formula 2, n is 4, 5 or 6, and R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 and R 19 is independently -OH, substituted or unsubstituted alkoxy having 1 to 4 carbons, or substituted or unsubstituted alkylthio having 1 to 4 carbons.

[0022] As used herein, the term 'comprising' means 'including' and is intended not to exclude the presence of additional ingredients, unless the context clearly indicates otherwise, for example, when the ingredients together add up to 100%.

[0023] In one specific example, the compound represented by the above chemical formula 1 may refer to lanosterol and its derivatives.

[0024] The term “lanosterol and derivatives thereof” in this specification may include at least one selected from the group consisting of lanosterol, inotodiol, trametenolic acid, ganodermadiol, and ganodermatriol.

[0025] The IUPAC name of the above "Inotodiol" is (3S,5R,10S,13R,14R,17R)-17-[(2S,3R)-3-hydroxy-6-methylhept-5-en-2-yl]- 4,4,10,13,14-pentamethyl-2,3,5,6,7,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-ol ((3S,5R,10S,13R,14R,17R)-17-[(2S,3R)-3-hydroxy-6- [methylhept-5-en-2-yl]-4,4,10,13,14-pentamethyl-2,3,5,6,7,11,12,15,16,17- decahydro-1H-cyclopenta[a]phenanthren-3-ol). The above inotodiol is a major physiologically active component of chaga mushroom (Inonotus obliquus), and can be chemically synthesized according to a conventional method, and can be manufactured as a pharmaceutically acceptable salt or separated and purified from a chaga mushroom extract. The above inotodiol compound can exist in the form of a pharmaceutically acceptable salt.

[0026] The term "pharmaceutically acceptable salt" as used herein encompasses all acid or base addition salts and their stereochemically isomeric forms, and may be, for example, addition salts of organic or inorganic acids. The salts include, but are not limited to, any salt that maintains the activity of the parent compound in the administered subject and does not cause undesirable effects.

[0027] These salts include inorganic and organic salts, for example, acetic acid, nitric acid, aspartic acid, sulfonic acid, sulfuric acid, maleic acid, glutamic acid, formic acid, succinic acid, phosphoric acid, phthalic acid, tannic acid, tartaric acid, hydrobromic acid, propionic acid, benzenesulfonic acid, benzoic acid, stearic acid, lactic acid, bicarboxylic acid, bisulfuric acid, bitartaric acid, oxalic acid, butyric acid, calcium idet, carbonic acid, chlorobenzoic acid, citric acid, idetic acid, toluenesulfonic acid, fumaric acid, gluceptic acid, esilinic acid, pamoic acid, gluconic acid, methylnitric acid, malonic acid, hydrochloric acid, hydroiodoic acid, hydroxynaphtholic acid, isethionic acid, lactobionic acid, mandelic acid, mucic acid, It can be naphthylic acid, muconic acid, p-nitromethanesulfonic acid, hexamic acid, pantothenic acid, monohydrogenphosphoric acid, dihydrogenphosphoric acid, salicylic acid, sulfamic acid, sulfanilinic acid, or methanesulfonic acid.

[0028] In addition, the salt forms include salts of alkali and alkaline earth metals, such as ammonium salts, lithium salts, sodium salts, potassium salts, magnesium salts, and calcium salts, salts with organic bases, such as benzathine, N-methyl-D-glucamine, and hydrabamine salts, and salts with amino acids, such as arginine and lysine. In addition, the salt forms can be converted into free forms by treatment with a suitable base or acid.

[0029] The term “inclusion” as used herein refers to a stoichiometric molecular phenomenon in which a guest molecule is captured by interaction with the cavity of a cyclodextrin molecule.

[0030] The term “cyclodextrin (CD)” used herein refers to a cyclic compound in which glucose is linked as a basic unit via an α-(1→4)-glycosidic bond. The cyclodextrin is a ring-shaped sugar particle with a cavity, and can be classified into alpha (α), beta (β), and gamma (γ) types depending on the structure. The internal pores of the cyclodextrin according to the structure are 5.3 Å for α-cyclodextrin, 6.5 Å for β-cyclodextrin, and 8.3 Å for γ-cyclodextrin. Since the outside of the cyclodextrin ring has a hydroxyl group, it is hydrophilic, whereas the inside is hydrophobic. Substances having a molecular structure suitable for the internal structure of the cyclodextrin can be incorporated into the hydrophobic internal cavity of the cyclodextrin to form an inclusion compound. In one specific example, the inotodiol may be enclosed in the internal cavity of the cyclodextrin.

[0031] In one specific example, the cyclodextrin derivative represented by the above chemical formula 2 may be γ-cyclodextrin represented by the following chemical formula 3.

[0032] [Chemical Formula 3]

[0033]

[0034] In one specific example, the pharmaceutical formulation may be a mixture of lanosterol and a derivative thereof or a pharmaceutically acceptable salt thereof and cyclodextrin in a molar ratio of 1:1 to 10. Specifically, the formulation may be a mixture of lanosterol and a derivative thereof and cyclodextrin in a molar ratio of 1:1 to 10, 1:1 to 9, 1:1 to 8, 1:1 to 7, 1:1 to 6, 1:1 to 5, 1:1 to 4, 1:1 to 3, or 1:1 to 2. For example, inotodiol and cyclodextrin may be mixed in a molar ratio of 1:3 to form an inclusion complex in which inotodiol is enclosed in a cavity of cyclodextrin.

[0035] In addition, the pharmaceutical formulation may increase the water solubility of the hydrophobic lanotodiol or its derivative by encapsulating the lanotodiol or its derivative in a cyclodextrin derivative. According to one specific example, the pharmaceutical formulation may increase the bioavailability and anti-inflammatory effect of lanotodiol or its derivative.

[0036] Meanwhile, in one specific example, the formulation may be a solid formulation or a liquid formulation.

[0037] The above solid preparation may be manufactured as any one selected from the group consisting of tablets, capsules, powders, dispersible granules, cachets and suppositories, sustained-release and delayed-release formulations.

[0038] The above liquid preparation may be prepared as any one selected from the group consisting of solutions, suspensions, emulsions, injectable formulations, solutions or sprays for nasal, buccal or sublingual administration, aerosol formulations suitable for inhalation, transdermal formulations, creams, lotions and formulations that can be incorporated into transdermal patches.

[0039] In one specific embodiment, the formulation may further comprise a pharmaceutically acceptable additive.

[0040] The above additive may be at least one selected from the group consisting of a diluent, a binder, a disintegrant, and a lubricant.

[0041] The diluent may be at least one selected from the group consisting of lactose, cellulose powder, microcrystalline cellulose, silicified microcrystalline cellulose, starch, pregelatinized starch, calcium carbonate, cyclodextrin, calcium sulfate, calcium silicate, magnesium carbonate, dicalcium phosphate, tricalcium phosphate, magnesium trisilicate, potassium chloride, sodium chloride, dibasic calcium phosphate dihydrate, tribasic calcium phosphate, kaolin, magnesium carbonate, magnesium oxide, mannitol, maltitol, sorbitol, xylitol, lactose, dextrose, maltose, sucrose, glucose, fructose, maltodextrin, dextrates, dextrins, and combinations thereof.

[0042] The above binder may be at least one selected from the group consisting of povidone, hydroxypropyl cellulose, hydroxypropyl methylcellulose, light anhydrous silicic acid, aluminum silicate, calcium silicate, calcium hydrogen phosphate, calcium carbonate, and combinations thereof.

[0043] The disintegrant may be at least one selected from the group consisting of croscarmellose sodium (CrosCMC-Na), carboxymethylcellulose, crospovidone (cross-linked polyvinylpyrrolidone), LHPC (low-substituted hydroxypropylcellulose), starch, sodium carboxymethyl starch, sodium starch glycolate, partially hydrolyzed starch, and combinations thereof.

[0044] The above lubricant may be at least one selected from the group consisting of magnesium stearate, fumaric acid, stearic acid, calcium stearate, sodium stearyl fumarate, polyethylene glycol, starch, talc, highly dispersed (colloidal) silica, magnesium oxide, magnesium carbonate, glyceryl behenate, glyceryl monostearate, silicon dioxide, calcium silicate, magnesium silicate, and combinations thereof.

[0045] The above formulation may contain additional excipients commonly used in the art. Such additional excipients may include plasticizers, film formers, colorants, anti-tacking agents, and / or pigments for coating the composition of the present invention. Additional types of excipients that may be present include buffers, flavoring agents, sweeteners, antioxidants, and / or absorption promoters.

[0046] The coating agent for coating the above formulation may be at least one selected from the group consisting of polyvinylpyrrolidone (PVP), hydroxypropylmethylcellulose (HPMC), carboxymethylcellulose (sodium salt and calcium salt), ethylcellulose, methylcellulose, hydroxyethylcellulose, ethylhydroxyethylcellulose, hydroxypropylcellulose (HPC), L-HPC (low-substituted HPC), polyvinyl alcohol, polymers of acrylic acid and its salts, vinylpyrrolidone-vinylacetate copolymers, gelatin, guar gum, partially hydrolyzed starch, alginate, xanthan, and combinations thereof.

[0047] The inclusion compound comprising the compound represented by the above formula 1 or a pharmaceutically acceptable salt thereof; and the cyclodextrin derivative represented by the above formula 2; can be purified, if necessary, by any method known to those skilled in the art. It should be noted that those skilled in the art are familiar with purification methods when such purification methods can be performed. For example, in a multi-step synthesis that helps to arrive at a particular compound, the purification steps can be performed after all of the synthetic steps, after all of the steps, at various points during the synthesis, and / or at the very end of the synthesis. In some methods, one or more of the purification steps comprises a technique selected from the group consisting of silica gel column chromatography, C-18 reversed-phase column chromatography, gel permeation column chromatography, HPLC (high-performance liquid chromatography), and LC (liquid chromatography).

[0048] Another aspect provides a method for preparing a formulation comprising the step of mixing a compound represented by the following chemical formula 1 or a pharmaceutically acceptable salt thereof; and a cyclodextrin derivative represented by the following chemical formula 2.

[0049] [Chemical Formula 1]

[0050]

[0051] [Chemical Formula 2]

[0052]

[0053] In the above chemical formula 1, R1 to R 10 is independently H, substituted or unsubstituted alkyl having C1 to C4, substituted or unsubstituted alkenyl having C2 to C4, substituted or unsubstituted alkynyl having C2 to C4, substituted or unsubstituted alkoxy having C1 to C4, halogen, hydroxy, aldehyde, carboxy, amino, nitro, or cyano,

[0054] In the above chemical formula 1 Is , , , or am.

[0055] In the above chemical formula 2, n is 4, 5 or 6, and R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 and R 19 is independently -OH, a substituted or unsubstituted alkoxy having 1 to 4 carbon atoms, or a substituted or unsubstituted alkylthio having 1 to 4 carbon atoms.

[0056] In one specific example, the compound represented by the above chemical formula 1 may refer to lanosterol and its derivatives. Lanosterol and its derivatives, pharmaceutically acceptable salts thereof, and cyclodextrins are as described above.

[0057] In one specific example, the mixing step may be mixing the compound represented by the chemical formula 1 or a pharmaceutically acceptable salt thereof; and the cyclodextrin derivative represented by the chemical formula 2; at a molar ratio of 1:1 to 10.

[0058] The above manufacturing method may utilize a method such as ultrasonic treatment, high pressure homogenizer, high temperature treatment, lyophilization method, kneading method, or co-evaporation method.

[0059] In one specific example, the method may further include adding a surfactant to the mixture. The surfactant may include, but is not limited to, Tween 20, Tween 80, or sucrose ester. The surfactant may be added at a concentration of 0.1 to 5%.

[0060] According to the pharmaceutical formulation according to the daily aspect, the water solubility, stability in solution, and absorbability in the body are improved, thereby increasing bioavailability and enhancing the anti-inflammatory effect.

[0061] Figure 1 is a schematic diagram illustrating a method for producing a complex in which inotodiol is incorporated into cyclodextrin.

[0062] Figure 2 is a drawing showing the preparation of a complex in which inotodiol is incorporated into cyclodextrin.

[0063] Figures 3a and 3b are graphs that confirm the formation of cyclodextrin and inotodiol inclusion complexes through differential scanning calorimetry (DSC) analysis:

[0064] Figure 3a is a graph showing the results of DSC analysis after inotodiol was incorporated into beta-cyclodextrin, and Figure 3b is a graph showing the results of DSC analysis after inotodiol was incorporated into gamma-cyclodextrin.

[0065] Figure 4 is a graph showing the formation of an inclusion complex according to the mixing ratio of inotodiol and cyclodextrin.

[0066] Figure 5 is a graph showing the degradation rate of inotodiol and cyclodextrin inclusion complexes over time.

[0067] Figures 6a to 6d show the results of an anti-inflammatory efficacy evaluation for LPS using a mouse-derived macrophage cell line (Raw264.7):

[0068] Figure 6a is a photograph showing the expression levels of IL-6, IL-1β, and TNF-α of unconjugated inotodiol and inotodiol and cyclodextrin conjugated complexes, Figure 6b is a graph showing the relative expression levels of IL-6, Figure 6c is a graph showing the relative expression levels of IL-1β, and Figure 6d is a graph showing the relative expression levels of TNF-α.

[0069] Figure 7 shows the EC of unincorporated inotodiol and inotodiol and γ-cyclodextrin inclusion complex (inotodiol / γ-CD) in human mast cell line LUVA cells. 50 This is a graph showing the measurement results.

[0070] Figures 8a to 8d show the anti-inflammatory effect of inotodiol and cyclodextrin inclusion complex (inotodiol / CD) in a whole-body mouse model of sepsis:

[0071] Figure 8a is a schematic diagram showing the experimental process for confirming the anti-inflammatory effect in a whole-body sepsis mouse model, Figure 8b is a graph showing the results of measuring the body temperature after treating inotodiol and cyclodextrin inclusion complex after inducing inflammation in sepsis model mice, Figure 8c is a graph showing the results of confirming the expression level of pro-inflammatory cytokine IL-1β after treating inotodiol and cyclodextrin inclusion complex after inducing inflammation in sepsis model mice, Figure 8d is a graph showing the results of confirming the expression level of pro-inflammatory cytokine TNF-α after treating inotodiol and cyclodextrin inclusion complex after inducing inflammation in sepsis model mice (naive (2 mice), sham (3 mice), Dexa 4 mpk in water (2 mice), G1: inotodiol 0.25 (ino -γCD 0.25 mpk in saline) (4 mice), G2: inotodiol 0.5 (ino -γCD 0.5 mpk in saline) (4 mice), G3: inotodiol 1 (ino 1 mpk in oil) (4 mice), G4: inotodiol 4 (ino 4 mpk in oil) (4 mice)).

[0072] Figures 9a to 9c show the results of comparing the in vivo bioavailability of unconjugated inotodiol and inotodiol and cyclodextrin conjugated complexes according to the dose:

[0073] Figure 9a is a graph comparing the serum concentration of inotodiol after oral administration of unencapsulated inotodiol (0.5 mpk) and inotodiol and cyclodextrin inclusion complex (0.5 mpk) to mice, Figure 9b is a graph comparing the serum concentration of inotodiol after oral administration of unencapsulated inotodiol (1 mpk) and inotodiol and cyclodextrin inclusion complex (1 mpk) to mice, and Figure 9c is a graph comparing the serum concentration of inotodiol after oral administration of unencapsulated inotodiol (4 mpk) and inotodiol and cyclodextrin inclusion complex (4 mpk) to mice.

[0074] The present invention will be described in more detail through the following examples. However, these examples are provided for illustrative purposes only and the scope of the present invention is not limited to these examples.

[0075] Example 1. Preparation of inotodiol and cyclodextrin inclusion complex

[0076] 1.1 Preparation of inotodiol and γ-cyclodextrin inclusion complex

[0077] A complex in which inotodiol is incorporated into γ-cyclodextrin was prepared using the same method as in Figs. 1 and 2.

[0078] Specifically, γ-cyclodextrin was first dissolved in 9 ml of DDW in proportion to the molar ratio of inotodiol (1:1 to 1:10), and then 10 mg of inotodiol dissolved in 1 ml of EtOH was slowly injected at 15-second intervals during ultrasound treatment (firstly using a microtip: Amp 30%, 10 min; secondly using a flat tip: Amp 50%, 5 min). Then, the solution was incubated at 25°C for 24 h in a suspension state and dried in a freeze dryer (-45°C, 2-3 days) to prepare an inclusion complex. Additionally, various surfactants were added as adjuvants up to 0.1-5% to the suspension in the solution state after ultrasound treatment to improve the stability of the suspension.

[0079] 1.2 Confirmation of the formation of inotodiol and cyclodextrin inclusion complexes according to the type of cyclodextrin

[0080] The formation of the inclusion complex (inotodiol / CD) prepared in Example 1 was confirmed through differential scanning calorimetry (DSC) analysis.

[0081] Specifically, 2 mg of each dried sample was placed in a sealed aluminum pan, and the pan was heated from 25°C to 310°C at a rate of 10°C / min under a nitrogen atmosphere. An empty pan was used as a reference. Graphs confirming the formation of inotodiol and cyclodextrin inclusion complexes (inotodiol / CD) through DSC analysis are shown in FIGS. 3 and 3b.

[0082] Figure 3a is a graph showing the results of DSC analysis after inotodiol was incorporated into beta-cyclodextrin (β-CD), and Figure 3b is a graph showing the results of DSC analysis after inotodiol was incorporated into gamma-cyclodextrin (γ-CD).

[0083] As shown in Figures 3a and 3b, the melting peak (192°C) of inotodiol crystals (lipid crystals) was detected in the inclusion complex of inotodiol and β-cyclodextrin (β-CD), but was not detected in the inclusion complex of inotodiol and γ-cyclodextrin (γ-CD).

[0084] This means that cholesterol, which has a structure similar to inotodiol, forms an inclusion complex with β-cyclodextrin, but inotodiol has two methyl groups at the 4th carbon in the 1st ring and one methyl group at the 14th carbon between the 3rd and 4th rings, so it occupies a larger volume overall than cholesterol and forms an inclusion complex only in γ-cyclodextrin, which has a large internal hydrophobic cavity. In other words, the above results mean that inotodiol forms an inclusion complex only in γ-cyclodextrin, which has a large internal hydrophobic cavity.

[0085] 1.3 Confirmation of inclusion complex formation according to the mixing ratio of inotodiol and cyclodextrin

[0086] The formation of an inclusion complex (inotodiol / CD) was investigated according to the mixing ratio of inotodiol and cyclodextrin. The results are shown in Table 1 and Fig. 4.

[0087] Table 1 shows the results of inclusion when inotodiol and cyclodextrin are mixed in a molar ratio of 1:1 to 5, and Figure 4 is a graph showing the formation of an inclusion complex according to the mixing ratio (molar ratio) of inotodiol and cyclodextrin.

[0088] As shown in Table 1 and Figure 4, when inotodiol and γ-cyclodextrin were mixed in a molar ratio of 1:3 to 5, it was confirmed that inotodiol was completely encapsulated in γ-cyclodextrin.

[0089] Inotodiol (mg)mJmJ / mgYield of complexation (%)PM 1:50.137.9161.8901:10.5126.3051.6816.511:20.2912.1541.6732.671:30.20>951:50.13>95

[0090]

[0091] Experimental Example 1. Determination of the decomposition rate of the inclusion complex (inotodiol / CD)

[0092] In order to confirm the release efficiency of inotodiol from the inclusion complex (inotodiol / CD), the decomposition rate of the inclusion complex (inotodiol / CD) prepared from Example 1 was confirmed.

[0093] Specifically, γ-cyclodextrin (γ-CD) and the inclusion complex (inotodiol / CD) of Example 1 were each dissolved in PBS (pH 7.5) to a concentration of 0.1 mg / ml. Then, 0.25 U / ml of porcine pancreatic α-amylase (PPA), which has the same drug active site as human and mouse pancreatic α-amylase and has a high similarity of 87.1% and 85.5%, respectively, was treated and reacted at 37°C and 100 rpm for 4 hours. The degree of hydrolysis was measured using the copper bicinchoninate method (CBC) for the reducing sugar maltose, a reaction decomposition product by α-amylase, and the results are shown in Table 2 and Fig. 5.

[0094] Table 2 shows the numerical results showing the decomposition rate over time of the inclusion complex (inotodiol / CD), and Figure 5 is a graph showing the decomposition rate over time of the inclusion complex (inotodiol / CD) of inotodiol and cyclodextrin.

[0095] Sample0 min10 min30 min60 min90 min120 min150 min180 min210 min240 minγ-CD(PPA 0.25 U)3.45 ±0.107.10 ±0.0215.04 ±0.0324.22 ±0.2533.07 ±0.4634.23 ±0.6234.85 ±0.5035.81 ±0.5437.56 ±0.6241.3 4 ±2. 41Ino / γ-CD(PPA 0.25 U)4.09 ±0.227.69 ±0.3513.57 ±0.3825.46 ±0.1730.20 ±0.6633.57 ±0.9636.81 ±0.0437.31 ±0.1238.76 ±0.5845.3 7 ±0. 04

[0096] As shown in Table 2 and Fig. 5, the degradation of the inclusion complex by PPA showed a relatively similar degradation rate to that of γ-cyclodextrin, and both showed a rapid degradation rate from the initial stage to 90 minutes. This means that the ring-opening reaction of γ-cyclodextrin can occur early, which can rapidly release inotodiol. In addition, the inotodiol and cyclodextrin inclusion complex (inotodiol / CD) showed a high degradation rate under the treatment of PPA, which has the same pharmacological activity site as human and mouse pancreatic α-amylase and has a high similarity of 87.1% and 85.5%, respectively. This means that the inclusion complex (inotodiol / CD) can be applied to humans and mice as well.

[0097]

[0098] Experimental Example 2. Comparison of the stability of unconjugated inotodiol and the conjugated complex (inotodiol / CD) in solution.

[0099] The solution stability of the inclusion complex (inotodiol / CD) prepared from Example 1 above was compared with that of unincorporated inotodiol.

[0100] Specifically, unencapsulated inotodiol or inotodiol and cyclodextrin inclusion complex (inotodiol / CD) was mixed with the prepared adjuvant. Concentrations of 100 to 15,000 ppm based on the weight of inotodiol were prepared and treated using a sonic bath at 50°C for 30 minutes. After leaving it at room temperature for 24 hours, stability was determined by visually observing whether precipitation occurred.

[0101] As a result, as shown in Table 3, it was confirmed that the inclusion complex (inotodiol / CD) was more stable in solution than the unincorporated inotodiol.

[0102] ppm of inotodiol in solutionCE9A215CE9A215 / CDTween 80 (1%)100 <1500Kolliphor (5%)500 <15000

[0103]

[0104] Experimental Example 3. Comparison of the physiological activities of inotodiol and inotodiol and γ-cyclodextrin inclusion complexes.

[0105] 3.1 Comparison of anti-inflammatory effects in mouse-derived macrophage cell line (Raw264.7)

[0106] The anti-inflammatory effects of the inclusion complex (inotodiol / CD) of Example 1 and unincorporated inotodiol were compared in a mouse-derived macrophage cell line (Raw264.7).

[0107] Specifically, Raw264.7 is 0.8 X 10 6Cells were seeded in 96-well plates and cultured overnight, and then pretreated with inotodiol and inotodiol and cyclodextrin inclusion complexes at various concentrations for 2 hours. After treatment with lipopolysaccharide (LPS) at a concentration of 0.1 μg / ml and cultured for 4 hours to induce inflammation, RNA was extracted, and the mRNA expression of IL-6, IL-1β, and TNF-α was confirmed by reverse transcription polymerase chain reaction (RT-PCR). The results are shown in Figures 6a to 6d.

[0108] Figure 6a is an electrophoresis image showing the mRNA expression levels of IL-6, IL-1β, and TNF-α when treated with unconjugated inotodiol and inotodiol and cyclodextrin inclusion complex, and Figures 6b to 6d are graphs showing the numerical quantification of the bands of the electrophoresis image using GAPDH. Figure 6b is a graph showing the relative mRNA expression level of IL-6, Figure 6c is a graph showing the relative mRNA expression level of IL-1β, and Figure 6d is a graph showing the relative mRNA expression level of TNF-α.

[0109] As shown in Figures 6a to 6d, in the case of unencapsulated inotodiol, the expression levels of IL-6 and TNF-α mRNA were significantly reduced when treated with 5 ug / ml, and in the case of inotodiol and γ-cyclodextrin inclusion complex (inotodiol / γ-CD), the expression levels of IL-6, IL-1β, and TNF-α mRNA were significantly reduced at all concentrations. This means that inotodiol and γ-cyclodextrin inclusion complex (inotodiol / γ-CD) exhibits more effective anti-inflammatory efficacy than unencapsulated inotodiol.

[0110] 3.2 Comparison of mast cell degranulation inhibition effects in LUVA cells

[0111] The mast cell degranulation inhibitory effects of unencapsulated inotodiol and the inotodiol and γ-cyclodextrin inclusion complex (inotodiol / γ-CD) of Example 1 were compared in a human mast cell cell line (LUVA cell).

[0112] Specifically, LUVA cells were 1 X 10 5 Cells were seeded in 96-well plates and cultured for 1 hour, then treated with inotodiol and inotodiol and cyclodextrin inclusion complexes at various concentrations. After treating with IgE at a concentration of 1 μg / ml, cultured overnight, and removing the supernatant, 50 μl of Tyrode buffer (130 mM NaCl, 5 mM KCl, 1 mM MgCl2, 1.4 mM CaCl2.2H2O, 10 mM HEPES, 5.6 mM glucose, 0.1% BSA) was dispensed into each well. Inotodiol and inotodiol and cyclodextrin inclusion complexes were treated at the same concentrations as before, and 20 μl of 2 μM A23187 and 10 μg / ml anti-human IgE antibody complex were dispensed into each well and incubated for 2 hours. Take 50 μ of the supernatant and mix with 50 μl of 2 mM p-nitrophenyl N-acetyl-bD-glucosamine, incubate for 2 hours, and measure the absorbance at 405 nm. Add 75 μl of 0.1 mM Triton X-100 to the cells remaining on the plate, store at 4℃ for 40 minutes to lyse, then take 50 μ and mix with 50 μl of 2 mM p-nitrophenyl N-acetyl-bD-glucosamine, incubate for 1 hour, and measure the absorbance at 405 nm. The absorbance of the supernatant and cell lysate was substituted into the equation below to calculate the degranulation rate, and the drug concentration (EC) required to reduce the degranulation rate by half compared to the untreated group 50 ) were compared and the results are shown in Figure 7.

[0113]

[0114] (T: absorbance of supernatant, L: absorbance of cell lysate)

[0115]

[0116] Figure 7 shows the degranulation rate and EC when treated with inotodiol and inotodiol / γ-CD inclusion complexes that were not incorporated into LUVA cells. 50 This is a graph showing the measurement results.

[0117] As shown in Figure 7, it was confirmed that the inotodiol and γ-cyclodextrin inclusion complex (inotodiol / γ-CD) effectively inhibited mast cell degranulation at a relatively low concentration compared to unincorporated inotodiol.

[0118] In addition, when inflammatory stimuli were given with two types of calcium ionophore + PMA, the required concentration of the drug that could inhibit mast cell degranulation by more than 50% was confirmed to be about half lower in the case of inotodiol and γ-cyclodextrin inclusion complex (inotodiol / γ-CD) compared to unincorporated inotodiol.

[0119] 3.3 Comparison of anti-inflammatory effects in a whole-body mouse model of sepsis

[0120] The anti-inflammatory effect of the inotodiol and cyclodextrin inclusion complex (inotodiol / CD) of Example 1 above was confirmed in a sepsis whole-body mouse model.

[0121] Specifically, the effect of the inclusion complex (inotodiol / CD) of Example 1 on clinical symptoms caused by LPS-activated macrophages was confirmed in a whole-body sepsis mouse model. As shown in Fig. 8a, mice were pretreated with 0.5 and 4 mg / kg of the inclusion complex, which was prepared by mixing inotodiol and γ-cyclodextrin in a 1:3 ratio, for 4 consecutive days, and then LPS (5 mg / kg) was injected intraperitoneally 1 hour after the last treatment.

[0122] Meanwhile, the body temperature of mice was measured every two hours, starting four hours after LPS-induced inflammation. Furthermore, the proinflammatory cytokines TNF-α and IL-1β, induced by LPS-activated macrophages, were measured using ELISA by collecting blood from mice two and six hours after LPS-induced inflammation, respectively.

[0123] The anti-inflammatory effect of the inotodiol and cyclodextrin inclusion complex (inotodiol / CD) confirmed through the above experimental process is shown in Figures 8b to 8d.

[0124] Figure 8b is a graph showing the results of measuring body temperature after treating inotodiol and cyclodextrin inclusion complexes in a sepsis model mouse after inducing inflammation, Figure 8c is a graph showing the results of confirming the expression level of proinflammatory cytokine IL-1β after treating inotodiol and cyclodextrin inclusion complexes in a sepsis model mouse after inducing inflammation, and Figure 8d is a graph showing the results of confirming the expression level of proinflammatory cytokine TNF-α after treating inotodiol and cyclodextrin inclusion complexes in a sepsis model mouse after inducing inflammation.

[0125] In Figures 8b to 8d, the Naive group represents the group administered only the same amount of vehicle solution (2 mice), the Sham group represents the group treated only with LPS (3 mice), and the Dexa group represents the group treated with 4.0 mg / kg (mpk) of dexamethasone as a positive control (2 mice). The G1 group represents the group treated with 0.25 mg / kg (mpk) of the inclusion conjugate (inotodiol / γCD) dissolved in saline (4 mice), the G2 group represents the group treated with 0.5 mg / kg (mpk) of the inclusion conjugate (inotodiol / γCD) dissolved in saline (4 mice), the G3 group represents the group treated with 1 mg / kg (mpk) of inotodiol dissolved in oil (4 mice), and the G4 group represents the group treated with 4 mg / kg (mpk) of inotodiol dissolved in oil (4 mice).

[0126] Data are expressed as the mean ± SD of mice in each group. Statistical significance was determined by one-way ANOVA followed by Bonferroni post-hoc test and is expressed as follows: p<0.005 (*), p<0.05 (#) compared to LPS treatment alone.

[0127] As shown in Figure 8b, the body temperature of mice was lowest in the Sham group treated only with LPS, and highest in the Naive group administered only the same amount of vehicle solution. The Dexa group and groups G1 to G4 showed a rectal temperature distribution between 35 and 36°C.

[0128] This is because, compared to the Naive group, which showed normal body temperature, the Sham group showed a significant decrease in body temperature due to anaphylaxis, but the anaphylactic reaction was reduced by inotodiol administration, preventing or recovering the decrease in body temperature.

[0129] In addition, as shown in FIGS. 8c and 8d, it was confirmed that the expression of proinflammatory cytokines (IL-1β, TNF-α) was reduced when treated with inotodiol and cyclodextrin inclusion complex (inotodiol / CD).

[0130] In particular, in the case of the expression level of IL-1β (Fig. 8c), not only was the expression level of the pro-inflammatory cytokine (IL-1β) significantly reduced compared to the group treated with only LPS, but it was also confirmed that the expression level of IL-1β was reduced when treated with the inotodiol and cyclodextrin inclusion complex (inotodiol / CD) compared to when treated with inotodiol dissolved in oil.

[0131] This means that the above-mentioned encapsulated complex not only has an anti-inflammatory effect, but also has a more significant anti-inflammatory effect than unencapsulated inotodiol.

[0132]

[0133] Experimental Example 4. Comparison of bioavailability of inotodiol and inclusion complex (inotodiol / CD)

[0134] The bioavailability of the inclusion complex (inotodiol / CD) of Example 1 and the non-encapsulated itonodiol in cyclodextrin were compared at each concentration.

[0135] Specifically, unconjugated inotodiol was dissolved in 0.9% saline containing 1% Tween 80, and the inclusion complex (inotodiol / CD) was dissolved only in 0.9% saline, and then 200 μl of the preparation corresponding to 0.5, 1, and 4 mg / kg (mpk) were orally administered to ICR male mice (30 g). Blood was collected at predetermined times (0.5, 1, 2, 3, and 6 h) after oral administration. The collected blood samples were centrifuged to separate the plasma, and the concentration of inotodiol in the plasma was measured through LC-MS analysis to investigate whether bioavailability was improved. The results are shown in Figs. 9a to 9c.

[0136] Figure 9a is a graph comparing the serum concentration of inotodiol after oral administration of unencapsulated inotodiol (0.5 mpk) and inotodiol and cyclodextrin inclusion complex (0.5 mpk) to mice, Figure 9b is a graph comparing the serum concentration of inotodiol after oral administration of unencapsulated inotodiol (1 mpk) and inotodiol and cyclodextrin inclusion complex (1 mpk) to mice, and Figure 9c is a graph comparing the serum concentration of inotodiol after oral administration of unencapsulated inotodiol (4 mpk) and inotodiol and cyclodextrin inclusion complex (4 mpk) to mice.

[0137] As shown in Figures 9a to 9c, the inclusion complex (inotodiol / CD) was found to have higher bioavailability than unencapsulated inotodiol. Specifically, it was confirmed that the concentration of inotodiol in mouse serum was generally higher in the case of the inclusion complex (inotodiol / CD) than in the case of unencapsulated inotodiol. This means that the inclusion complex (inotodiol / CD) has higher bioavailability than unencapsulated inotodiol.

Claims

1. A compound represented by the following chemical formula 1 or a pharmaceutically acceptable salt thereof; and A pharmaceutical formulation comprising a cyclodextrin derivative represented by the following chemical formula 2: [Chemical Formula 1] [Chemical Formula 2] In the above chemical formula 1, R1 to R 10 is independently H, substituted or unsubstituted alkyl having C1 to C4, substituted or unsubstituted alkenyl having C2 to C4, substituted or unsubstituted alkynyl having C2 to C4, substituted or unsubstituted alkoxy having C1 to C4, halogen, hydroxy, aldehyde, carboxy, amino, nitro, or cyano, In the above chemical formula 1 Is , , , or am. In the above chemical formula 2, n is 4, 5 or 6, and R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 and R 19 is independently -OH, substituted or unsubstituted alkoxy having 1 to 4 carbons, or substituted or unsubstituted alkylthio having 1 to 4 carbons.

2. A pharmaceutical formulation according to claim 1, wherein the compound represented by the chemical formula 1 or a pharmaceutically acceptable salt thereof is enclosed within a cyclodextrin derivative represented by the chemical formula 2.

3. A pharmaceutical formulation according to claim 1, wherein the compound represented by the chemical formula 1 and the cyclodextrin derivative represented by the chemical formula 2 are mixed at a molar ratio of 1:1 to 10.

4. A pharmaceutical formulation according to claim 1, wherein the compound represented by the chemical formula 1 comprises at least one selected from the group consisting of lanosterol, inotodiol, trametenolic acid, ganodermadiol, and ganodermatriol.

5. A pharmaceutical formulation according to claim 1, wherein the cyclodextrin derivative represented by the chemical formula 2 is gamma-cyclodextrin represented by the chemical formula 3 below. [Chemical Formula 3] 6. A pharmaceutical formulation according to claim 1, wherein the formulation is a solid formulation or a liquid formulation.

7. A pharmaceutical formulation according to claim 6, wherein the solid formulation is prepared as any one selected from the group consisting of tablets, capsules, powders, dispersible granules, cachets, suppositories, sustained-release and delayed-release formulations.

8. A pharmaceutical formulation according to claim 6, wherein the liquid formulation is prepared as any one selected from the group consisting of a solution, a suspension, an emulsion, an injectable formulation, a solution or spray for nasal, buccal or sublingual administration, an aerosol formulation suitable for inhalation, a transdermal formulation, a cream, a lotion and a formulation that can be incorporated into a transdermal patch.

9. A pharmaceutical formulation according to claim 1, further comprising a pharmaceutically acceptable additive.

10. A pharmaceutical formulation according to claim 9, wherein the additive is at least one selected from the group consisting of a diluent, a binder, a disintegrant, and a lubricant.

11. A pharmaceutical formulation according to claim 10, wherein the diluent is at least one selected from the group consisting of lactose, cellulose powder, microcrystalline cellulose, silicified microcrystalline cellulose, starch, pregelatinized starch, calcium carbonate, cyclodextrin, calcium sulfate, calcium silicate, magnesium carbonate, dicalcium phosphate, tricalcium phosphate, magnesium trisilicate, potassium chloride, sodium chloride, dibasic calcium phosphate dihydrate, tribasic calcium phosphate, kaolin, magnesium carbonate, magnesium oxide, mannitol, maltitol, sorbitol, xylitol, lactose, dextrose, maltose, sucrose, glucose, fructose, maltodextrin, dextrates, dextrin, and combinations thereof.

12. A pharmaceutical formulation according to claim 10, wherein the binder is at least one selected from the group consisting of povidone, hydroxypropyl cellulose, hydroxypropyl methylcellulose, light anhydrous silicic acid, aluminum silicate, calcium silicate, calcium hydrogen phosphate, calcium carbonate, and combinations thereof.

13. A pharmaceutical formulation according to claim 10, wherein the disintegrant is at least one selected from the group consisting of croscarmellose sodium (CrosCMC-Na), carboxymethylcellulose, crospovidone (cross-linked polyvinylpyrrolidone), L-HPC (low-substituted hydroxypropylcellulose), starch, sodium carboxymethyl starch, sodium starch glycolate, partially hydrolyzed starch, and combinations thereof.

14. A pharmaceutical formulation according to claim 10, wherein the lubricant is at least one selected from the group consisting of magnesium stearate, fumaric acid, stearic acid, calcium stearate, sodium stearyl fumarate, polyethylene glycol, starch, talc, highly dispersed (colloidal) silica, magnesium oxide, magnesium carbonate, glyceryl behenate, glyceryl monostearate, silicon dioxide, calcium silicate, magnesium silicate, and combinations thereof.

15. A compound represented by the following chemical formula 1 or a pharmaceutically acceptable salt thereof; and A method for producing a formulation comprising the step of mixing a cyclodextrin derivative represented by the following chemical formula 2: [Chemical Formula 1] [Chemical Formula 2] In the above chemical formula 1, R1 to R 10 is independently H, substituted or unsubstituted alkyl having C1 to C4, substituted or unsubstituted alkenyl having C2 to C4, substituted or unsubstituted alkynyl having C2 to C4, substituted or unsubstituted alkoxy having C1 to C4, halogen, hydroxy, aldehyde, carboxy, amino, nitro, or cyano, In the above chemical formula 1 Is , , , or am. In the above chemical formula 2, n is 4, 5 or 6, and R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 and R 19 is independently -OH, substituted or unsubstituted alkoxy having 1 to 4 carbons, or substituted or unsubstituted alkylthio having 1 to 4 carbons.

16. A method for manufacturing a formulation according to claim 15, wherein the mixing step comprises mixing a compound represented by chemical formula 1 or a pharmaceutically acceptable salt thereof; and a cyclodextrin derivative represented by chemical formula 2; at a molar ratio of 1:1 to 10.

17. A method for manufacturing a formulation according to claim 16, further comprising a step of adding a surfactant to the mixture.

Citation Information

Patent Citations

  • Neutral stabilization complex for CI-979 HCl, a cognition activator

    US5362860A

  • Ganodenic acid monomer Me cyclodextrin inclusion compound and preparation method of oral solid preparation thereof

    CN101623502A

  • Preparation, medical application and composition of 20S-protopanaxadiol beta-cyclodextrin inclusion compound

    CN102178956A

  • Sterol-containing cell culture medium suitable for filtration sterilization

    JP6442808B1

  • Safty helmet integrated management system

    KR1020230121492A